CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
Inobrodib is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma ASH is the annual flagship scientific and clinical haematology meeting which is taking place in New Orleans on 9-13 December 2022 […]
